Showing 1 to 2 of 2 results


Lenacapavir: 99.9% Effective HIV Prevention in Clinical Trials
Lenacapavir, a new HIV drug, demonstrated 99.9% effectiveness in preventing infection in a recent study of over 2,000 participants across diverse genders, representing a significant advancement in PrEP and potentially revolutionizing HIV prevention strategies.
Lenacapavir: 99.9% Effective HIV Prevention in Clinical Trials
Lenacapavir, a new HIV drug, demonstrated 99.9% effectiveness in preventing infection in a recent study of over 2,000 participants across diverse genders, representing a significant advancement in PrEP and potentially revolutionizing HIV prevention strategies.
Progress
48% Bias Score

Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.

Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.
Progress
60% Bias Score
Showing 1 to 2 of 2 results